ReCOMmendations for the treatment of INFLUENZA in children for Primary care physiciAnS – COMPAS INFLUENZA

• Authors: Doniec Zbigniew , Mastalerz-Migas Agnieszka , Jackowska Teresa , Kuchar Ernest , Sybilski Adam

Abstracts

EN

Influenza is an acute infectious disease of the airways that occurs in every age group. The course of the disease may have a different severity and clinical picture, from asymptomatic to severe with symptoms of respiratory failure. The possibilities of pandemic infections and serious complications throughout the course of influenza distinguish it from other viral respiratory diseases, prompting us to treat it in a special way. Diagnosis of the disease is usually clinical in nature, and additional studies may be helpful in clinically relevant cases. The drug recommended for treatment and chemoprophylaxis is oseltamivir. Clinical benefits are greatest if treatment starts as early as possible, within 48 hours of the first symptoms of influenza. Clinical studies indicate that early treatment with oseltamivir may shorten the duration of the disease and reduce the risk of its complications. Annual influenza vaccination is the most effective method of preventing this disease, and the only contraindication to vaccination is the occurrence of an anaphylactic or other severe allergic reaction after a previous vaccination

Keywords

EN

influenza; children; treatment; vaccinations.

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2019
• Issue: 2
• Pages: 189-198

Contributors

author

Doniec Zbigniew

author

Mastalerz-Migas Agnieszka

author

Jackowska Teresa

author

Kuchar Ernest

author

Sybilski Adam

References

• Antczak A. Grypa. Praktyczne kompendium. Warszawa: Medical Tribune Polska; 2015 (in Polish).
• Mastalerz-Migas A. Grypa, od rozpoznania do leczenia. Praktyczny przewodnik dla lekarzy podstawowej opieki zdrowotnej. Poznań:Biofarm; 2018 (in Polish).
• Long JS, Mistry B, Haslam SM, et al. Host and viral determinants of influenza A virus species specificity. Nat Rev Microbiol 2019; 17(2):67–81, doi: 10.1038/s41579-018-0115-z.
• Kim H, Webster RG , Webby RJ. Influenza Virus: dealing with a drifting and shifting pathogen. Viral Immunol 2018; 31(2): 174–183.
• Antczak A, Jahnz-Różyk K, Krzywański J, et al. Rekomendacje ekspertów Ogólnopolskiego Programu Zwalczania Grypy dotyczące profilaktyki grypy w sezonie epidemicznym 2017/2018. Warszawa: FluForum; 2017 (in Polish).
• World Health Organization. Influenza [cited 21.12.2018]. Available from URL : https://www.who.int/influenza/gisrs_laboratory/flunet/en/.
• ECDC. Seasonal Influenza. Factsheet for health professionals 2017 [cited 21.12.2018]. Available from URL : https://ecdc.europa.eu/en/seasonal-influenza.
• Demicheli V, Jefferson T, Al Ansary LA, et al. Vaccines for prevention influenza in healthy adults. Cochrane Database Syst Rev 2014; 3:CD001269, doi: 10.1002/14651858.CD001269.pub5.
• Hefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; 1:CD004879.
• Krajowy Ośrodek ds. Grypy – Meldunki Epidemiologiczne PZH [cited 21.12.2018]. Available from URL : https://www.pzh.gov.pl/ (in Polish).
• World Health Organization. Influenza [cited 18.12.2018]. Available from URL : https://www.who.int/influenza/en/.
• Center for Diseases Control and Prevention [cited 18.12.2018]. Available from URL :https://www.cdc.gov/flu/index.htm.
• Makowiec-Dyrda M, Tomasik T, Windak A, et al. Profilaktyka i leczenie grypy. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce, 2016.[cited 21.12.2018]. Available from URL : https://klrwp.pl/strona/225/wytyczne-grypa-2016/pl (in Polish).
• Chartrand C, Leeflang MM, Minion J, et al. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012; 156(7):500–511.
• Wang R, Taubenberger JK. Methods for molecular surveillance of ifluenza. Expert Rev Anti Infect Ther 2010; 8(5): 517–52716. Brydak LB, Wozniak-Kosek A, Nitsch-Osuch A. Influenza diagnosis and vaccination in Poland. Respir Physiol Neurobiol 2013; 187(1)88–93.:
• Rosa-Olivares J, Porro A, Rodriguez-Varela M, et al. Otitis media: to treat, to refer, to do nothing: a review for the practitioner. Pediatr Rev 2015; 36(11): 480–486.
• Kondrich J, Rosenthal M. Influenza in children. Curr Opin Pediatr 2017; 29(3): 297–302.
• Dawood FS, Chaves SS , Pérez A, et al. Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003–2010. J Infect Dis 2014; 209(5): 686–694, doi: 10.1093/infdis/jit473.
• Ghebrehewet S, MacPherson P, Ho A. Influenza. BMJ 2016; 7: 355, doi: https://doi.org/10.1136/bmj.i6258.
• . World Health Organization. Clinical management of human infection with pandemic influenza (H1N1) 2009: revised guidance. November 2009. Available from URL : www.who.int/csr/resources/publications.
• Uyeki TM. Influenza. Ann Intern Med 2017; 167(5): 33–48.
• Doniec Z, Mastalerz-Migas A, Krenke K, i wsp. Rekomendacje postępowania diagnostyczno-terapeutycznego w kaszlu dzieci dla lekarzy POZ. Lekarz POZ 2016; 4: 305–321 (in Polish).
• Mousa HA. Prevention and treatment of influenza, influenza-like illness, and common cold by herbal, complementary, and natural therapies. J Evid Based Complementary Altern Med 2017; 22(1): 166–174.
• Tamiflu – charakterystyka produktu leczniczego na dzień 31.08.2018. Available from URL : https://www.ema.europa.eu/documents/product-information/tamiflu-epar-product-information_pl.pdf (in Polish).
• Ebilfumin – charakterystyka produktu leczniczego na dzień 27.06.2018. Available from URL : https://www.ema.europa.eu/documents/product-information/ebilfumin-epar-product-information_en.pdf (in Polish).
• Tamivil – charakterystyka produktu leczniczego na dzień 19.11.2018. Available from URL : http://www.chpl.com.pl/#detail=39462504 !87951071 (in Polish).
• Malosh RE , Martin ET , Heikkinen T, et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis 2018; 66(10): 1492–1500.
• Davlin SL , Blanton L, Kniss K, et al. Influenza activity – United States, 2015–16 season and composition of the 2016–17 influenza vaccine.MMWR Morb Mortal Wkly Rep 2016; 65: 567–575.
• Garten R, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. MMWR Morb Mortal Wkly Rep 2018; 67(22): 634–642.
• Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.Lancet 2015; 385(9979): 1729–1737.
• Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14(2):109–118.
• Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1) pdm09 at high risk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis 2017; 64: 1328–1334.
• McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45(12): 1568–1575.
• AAP Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2018–2019. Pediatrics 2018; 142(4): e20182367.
• Grohskopf LA, Sokolow LZ , Broder KR , et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018–19 Influenza Season. MMWR Recomm Rep 2018; 67(3): 1–20, doi:10.15585/mmwr.rr6703a1.
• Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or metaanalyses. J Antimicrob Chemother 2017; 72(11): 2990–3007.
• Uyeki TM. Oseltamivir treatment of influenza in children. Clin Infect Dis 2018; 66(10): 1501–1503.
• Talbot HK. Influenza in older adults. Infect Dis Clin North Am 2017; 31(4): 757–766.
• Center Diseases Control and Prevention [cited 25.01.2019]. Available from URL : https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.html.
• Blank P, Falup-Pecurariu O, Kassianos G, i wsp. Szczepienia przeciw grypie: podstawowe fakty dla lekarzy pierwszego kontaktu w E uropie (RAISE ). Warszawa: Fundacja Nadzieja dla Zdrowia; 2016 (in Polish).
• Dziennik Urzędowy Ministra Zdrowia [cited 25.01.2019]. Available from URL : https://gis.gov.pl/wp-content/uploads/2018/01/akt.pdf (in Polish).
• Thompson MG, Jeffrey CK, Regan AK, et al. Influenza vaccine effectiveness in preventing influenza associated hospitalizations during pregnancy: a multicountry retrospective test negative design study, 2010–2016. Clin Infect Dis 2018, doi: 10.1093/cid/ciy737 [Epub ahead of print].
• Zaman K, Roy E, Arifeen SE , et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555–1564.
• Steinhoff MC, K atz J, E nglund JA, et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebocontrolled trial. Lancet Infect Dis 2017; 17(9): 981–989.
• Madhi SA, Cutland CL, Kuwanda L, et al. Maternal Flu Trial (Matflu) Team. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014; 371: 918–931.
• Tisa V, Barberis I, Faccio V, et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg 2016; 57(1): E28–E33
• Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2018–19 influenza season. MMWR Morb Mortal Wkly Rep 2018; 67(22): 643–645.
• Kelso JM, Greenhawt MJ, Li JT. Joint Task Force on Practice Parameters (JTFPP). Update on influenza vaccination of egg allergic patients.Ann Allergy Asthma Immunol 2013; 111(4): 301–302.
• Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017.Ann Allergy Asthma Immunol 2018; 120(1): 49–52, doi: 10.1016/j.anai.2017.10.020
• Public Health Agency of Canada. National Advisory Commitee on Immunisation (NACI) Canadian Immunization Guide Chapter on influenza and statement on seasonal influenza vaccine for 2017–2018. Ottawa, Ontario; 2017.
• AAP Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2017–2018. Pediatrics 2017; 140: e20172550.
• Grohskopf LA, Sokolow LZ , Broder KR , et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2017–18 Influenza Season. MMWR Recomm Rep 2017; 66: 1–20.54. Charakterystyka produktu leczniczego [cited 18.12.2019]. Available from URL : http://leki.urpl.gov.pl/files/40_VaxigripTetra.pdf (in polish).
• Charakterystyka produktu leczniczego [cited 18.12.2019]. Available from URL : https://gdziepolek.blob.core.windows.net/product-documents/doc59317/influvac-tetra-przeciw-grypie-dokument.pdf (in Polish).